期刊文献+

尼古丁抑制6-羟基多巴胺损伤诱导的T淋巴细胞浸润 被引量:1

Nicotine inhibits the infiltration of T lymphocytes produced by 6-hydroxydopamine lesion in the striatum of SD rat
原文传递
导出
摘要 目的采用6-羟基多巴胺(6-OHDA)部分损伤大鼠帕金森病模型,探讨尼古丁保护多巴胺能神经元的机制。方法雌性SD大鼠60只采用随机数字表法分为三组:尼古丁高剂量治疗组(尼古丁2.0mg/kg腹膜腔内注射1、低剂量治疗组(尼古丁0.2mg/kg腹膜腔内注射1及模型对照组(生理盐水腹膜腔内注射1,每组20只。注射7d后,分别接受单侧纹状体内6-OHDA20μg注射,制作帕金森病模型。免疫组织化学及体视学方法定量分析黑质多巴胺能神经元和纹状体CD3、CD4和CD8阳性淋巴细胞数量。结果6-OHDA注射4周后,模型对照组注射侧黑质酪氨酸羟化酶(TH)免疫阳性细胞为对照侧的25.27%;而在尼古丁低剂量和高剂量组,注射侧的TH免疫阳性细胞分别为相应对照侧的64.97%和67.24%。各组各时间点6-OHDA注射侧纹状体有明显的T淋巴细胞浸润。尼古丁治疗组浸润的T淋巴细胞数较模型对照组明显减少,差异有统计学意义(P〈0.051,而CD4和CD8阳性细胞占总T淋巴细胞的比例在各组和各时间点基本一致。尼古丁治疗组和模型对照组比较差异无统计学意义(P〉0.051。结论尼古丁可抑制6-OHDA损伤诱导的T淋巴细胞浸润,对抗6-OHDA神经细胞毒性,保护多巴胺能神经元。 Objective To explore the mechanism through which nicotine protects dopaminergic neurons against 6-hydroxydopamine (6-OHDA) toxicity in Parkinson's disease (PD) rat model. Methods Sixty Female SD rats were divided into 3 groups according to randomly digital table: High dosage group (nicotine 2 mg/kg, 5 injections i.p. per day at 2-h interval), low dosage group (nicotine 0.2 mg/kg, 5 injections i.p. per day at 2-h interval) and model group (normal saline treatment), n=20 each group. On day 8 after the treatment, a single injection of 20 μg of 6-OHDA was administered into striatum. Nicotine or normal saline was administered continuously daily until animals were killed. The dopaminergic neurons and CD3, CD4 and CD8-positive lymphocytes were analyzed quantitatively using immunohistochemistry and stereology. Results Four weeks after 6-OHDA administration, in the normal saline treated group, tyrosine hydroxylase-immunopositive cells in the substantia nigra of administered side was 25.27% of those in the one of non-administered side, and the immunopositive cells in 0.2 and 2 mg/kg nicotine treated groups were respectively 64.97% and 67.24% of those in the non-administered side. The loss of dopaminergic neurons induced by 6-OHDA in the substantia nigra was significantly less severe in the nicotine treatment groups (at both 0.2 and 2 mg/kg groups) than the saline treated group. T lymphocyte infiltration was markedly induced by 6-OHDA administration into striatum in all groups. In the striatum, we observed that the numbers ofCD3, CD4 and CD8-positive lymphocytes were reduced significantly in the nicotine treated animals as compared to saline controls (P〈0.05). The proportions of CD4 and CD8 positive cells in the total T lymphocytes were roughly equivalent in all groups at all time points, and there were no significant difference between nicotine treated groups and saline treated group. Conclusion Nicotine may have a neuroprotective effect against 6-OHDA induced dooaminergic lesion by inhibiting; the infiltration oft lymlahocytes and inflammation.
出处 《中华神经医学杂志》 CAS CSCD 2008年第7期665-669,共5页 Chinese Journal of Neuromedicine
基金 国家自然科学基金(30671950),国家十五攻关课题(2004BA720A03)
关键词 尼古丁 帕金森病 6-羟基多巴胺 T淋巴细胞 Nicotine Parkinson' s disease 6-OHDA T lymphocyte
  • 相关文献

参考文献9

  • 1Quik M. Smoking, nicotine and Parkinson's disease [J]. Trends Neurosci, 2004, 27(9): 561-568.
  • 2Jeyarasasingam G, Tompkins L, Quik M, et al. Stimulation of non alpha7 nicotinic receptors partially protects dopaminergic neurons from l-methyl-4-phenylpyridinium-induced toxicity in culture [J]. Neuroscience, 2002, 109(2): 275-285.
  • 3Mai H, May WS, Gao F, et al. A functional role for nicotine in Bcl-2 phosphorylation and suppression of apoptosis [J]. J Biol Chem, 2003, 278(3): 1886-1891.
  • 4Meshul CK, Kamel D, Moore C, et al. Nicotine alters striatal glutamate function and decreases the apomorphine-induced contralateral rotations in 6-OHDA-lesioned rats [J]. Exp Neurol, 2002, 175(1): 257-274.
  • 5Shytle RD, Mori T, Townsend K, et al. Cholinergic modulation of microglial activation by a7 nicotinic receptors [J]. J Neurochem, 2004, 89(2): 337-343.
  • 6Saeed RW, Varma S, Peng-Nemeroff T, et al. Cholinergic stimulation blocks endothelial cell activation and leukocyte recruitment during inflammation [J]. J Exp Med, 2005, 201 (7): 1113-1123.
  • 7徐胜利,周明,刘平,张丽艳,徐艳玲,张愚,陈彪.6-羟多巴诱导大鼠黑质的持续胶质细胞反应[J].神经解剖学杂志,2005,21(2):133-138. 被引量:6
  • 8Kurkowska-Jastrzebska I, Wronska A, Kohutnicka M, et al. MHC class Ⅱ positive microglia and lymphocytic infiltration are present in the substantia nigra and striatum in mouse model of Parkinson's disease[J]. Acta Neurobiol Exp, 1999, 59(1): 1-8.
  • 9Wu DC, Jackson-Lewis V, Vila M, et al. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine mouse model of Parkinson disease [J]. J Neurosci, 2002, 22(5): 1763-1771.

二级参考文献14

  • 1Vila M, Jackson-Lewis V, Guegan C et al. The role of glial cells in Parkinson's disease. Curr Opin Neurol, 2001; 14:483 - 489.
  • 2Przedborski S, Vila M. The 1-methy-4-phenyl-1, 2,3,6-tetrahydropridine mouse model: a toll to explore the pathogenesis of Parkinson's disease. Ann NY Acad Sci, 2003 ;991:189 -198.
  • 3Gao HM, Liu B, Zhang W et al. Critical role of microglial NADPH oxidase-derived free radicals in the in vitro MPTP model of Parkinson's disease. FASEB J, 2003; 17:1954 - 1956.
  • 4Sherer TB, Betarbet R, Kim JH et al. Selective microglial activation in the rat rotenone model of Parkinson's disease. Neurosci Lett, 2003 ;341:87 -90.
  • 5Rodrigues RW, Gomide VC, Chadi G. Astroglial and microglial reaction after a partial nigrostriatal degeneration induced by the striatal injection of different doses of 6-hydroxydopamine. Int J Neurosci, 2001 ;109:91 - 126.
  • 6Wu DC, Jackson-Lewis V, Vila M et al. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci,2002 ;22:1763 - 1771.
  • 7Kalla R, Liu ZQ, Xu SL et al. Microglia and the early phase of immune surveillance in the axtomized facial motor nucleus: impaired microglial activation and lymphocyte recruitment but not effect on neuronal survival or axonal regeneration in macrophage-colony stimulating factor-deficient mice. J Comp Neurol, 2001; 436: 182 -201.
  • 8Werner A, Kloss CUA, Walter J et al. Intercellular adhesion molecule-1 ( ICAM-1 ) in the regenerating mouse facial motor nucleus.J Neurocytol, 1998 ;27:219 - 232.
  • 9Teismann P, Tieu K, Cohen O et al. Pathogenic role of glial cells in Parkinson's disease. Mov Disord, 2003; 18:121 - 129.
  • 10Raivich G, Bohatschek M, Kloss CU et al. Neuroglial activation repertoire in the injured brain: graded response, molecular mechanisms and cues to physiological function. Brain Res Brain Res Rev, 1999 ;30:77 - 105.

共引文献5

同被引文献17

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部